BIIB: Biogen Inc. Stocks News on October 21, 2025

BIIB

MT Newswires

7 days ago

Wedbush Raises Price Target on Biogen to $135 From $129, Keeps Neutral Rating

1 Healthcare Stock to Research Further and 2 We Find Risky

BIIB

StockStory

7 days ago

1 Healthcare Stock to Research Further and 2 We Find Risky

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

BIIB

GlobeNewswire

7 days ago

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

BIIB

Simply Wall St.

8 days ago

Biogen (BIIB): Revisiting Valuation After Recent Pipeline and Partnership Developments

UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know

BIIB

StockStory

10 days ago

UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

BIIB

Zacks

10 days ago

Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?

Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

BIIB

PR Newswire

11 days ago

Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

BIIB

MT Newswires

11 days ago

Biogen, Stoke Therapeutics Present Positive Long-Term Data for Zorevunersen in Dravet Syndrome

BIIB

Simply Wall St.

18 days ago

Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength?

BIIB

StockStory

19 days ago

3 Low-Volatility Stocks That Concern Us

BIIB

Insider Monkey

19 days ago

Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT

S&P 500, Dow Reach New Peaks as Traders Look Past Ongoing Shutdown

BIIB

MT Newswires

19 days ago

S&P 500, Dow Reach New Peaks as Traders Look Past Ongoing Shutdown

Drug Stock Rally Helps Push Dow and S&P 500 to Records

BIIB

The Wall Street Journal

19 days ago

Drug Stock Rally Helps Push Dow and S&P 500 to Records

BIIB

MT Newswires

19 days ago

US Equity Indexes Rise as Healthcare Jumps, October Rate-Cut Certainty Increases Amid Surprise Fall in Private Payrolls

BIIB

MT Newswires

19 days ago

Healthcare Helps Lift US Equity Indexes After Federal Shutdown Begins

Equities Rise Intraday as Markets Look Past Shutdown

BIIB

MT Newswires

19 days ago

Equities Rise Intraday as Markets Look Past Shutdown

BIIB

MT Newswires

a month ago

Biogen Says Leqembi Approved in Australia as Treatment for Alzheimer's Disease; Shares Up Pre-Bell

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

BIIB

GlobeNewswire

a month ago

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

BIIB

MT Newswires

a month ago

Biogen Says US FDA Delays Approval of Spinal Muscular Atrophy Treatment

US FDA declines to approve higher dose of Biogen's genetic disorder drug

BIIB

Reuters

a month ago

US FDA declines to approve higher dose of Biogen's genetic disorder drug

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

BIIB

GlobeNewswire

a month ago

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

Biogen Gets EU Nod for First Postpartum Depression Drug

BIIB

Zacks

a month ago

Biogen Gets EU Nod for First Postpartum Depression Drug

BIIB

MT Newswires

a month ago

Biogen to Acquire Alcyone Therapeutics for Initial $85 million

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

BIIB

GlobeNewswire

a month ago

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

Biogen’s Zurzuvae approved as first postpartum depression drug in Europe

BIIB

Pharmaceutical Technology

a month ago

Biogen’s Zurzuvae approved as first postpartum depression drug in Europe

Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs

BIIB

BioPharma Dive

a month ago

Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs

BIIB

MT Newswires

a month ago

Biogen Gets EU Approval for Postpartum Depression Treatment

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

BIIB

GlobeNewswire

a month ago

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

BIIB

StockStory

a month ago

Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way

BIIB

Insider Monkey

a month ago

Canaccord Genuity Reiterates a Buy on Biogen (BIIB)

Does FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease?

BIIB

Simply Wall St.

a month ago

Does FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease?

BIIB

Insider Monkey

a month ago

H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects

Is Biogen Stock Underperforming the Nasdaq?

BIIB

Barchart

a month ago

Is Biogen Stock Underperforming the Nasdaq?

BIIB

MT Newswires

a month ago

Piper Sandler Adjusts Price Target on Biogen to $118 From $115, Maintains Neutral Rating

BIIB

Argus Research

a month ago

Weekly Stock List

BIIB

Simply Wall St.

a month ago

Why Biogen (BIIB) Is Up 6.4% After At-Home Alzheimer’s Therapy and Dravet Data Updates

BIIB

StockStory

2 months ago

Biogen (BIIB) Stock Trades Down, Here Is Why

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

BIIB

Insider Monkey

2 months ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

BIIB

MT Newswires

2 months ago

C4 Therapeutics Says Biogen's IND Application Accepted by FDA to Treat Autoimmune Diseases

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

BIIB

GlobeNewswire

2 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

BIIB

GlobeNewswire

2 months ago

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

BIIB

MT Newswires

2 months ago

US Equity Indexes Decline as Gains in Treasury Yields Push Mag-7 Lower

BIIB

MT Newswires

2 months ago

US Equity Markets End Lower Following Court Ruling Against Trump Tariffs

Stock Market Today: Dow Dives 500 Points On Trump Tariff News; Nvidia, Palantir Sell Off (Live Coverage)

BIIB

Investor's Business Daily

2 months ago

Stock Market Today: Dow Dives 500 Points On Trump Tariff News; Nvidia, Palantir Sell Off (Live Coverage)

Grand River Aseptic Manufacturing (GRAM) Appoints Denis Johnson as Chief Executive Officer

BIIB

GlobeNewswire

2 months ago

Grand River Aseptic Manufacturing (GRAM) Appoints Denis Johnson as Chief Executive Officer

These Stocks Are Moving the Most Today: Nvidia, PepsiCo, NIO, Biogen, Newmont, Signet, and More

BIIB

Barrons.com

2 months ago

These Stocks Are Moving the Most Today: Nvidia, PepsiCo, NIO, Biogen, Newmont, Signet, and More

BIIB

MT Newswires

2 months ago

Stoke Therapeutics, Biogen Say Studies Support Potential of Dravet Syndrome Treatment

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

BIIB

Business Wire

2 months ago

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

BIIB

GlobeNewswire

2 months ago

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

BIIB

Insider Monkey

2 months ago

Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries

Startup Corsera Health aims to bring preventive heart medicine to the masses

BIIB

BioPharma Dive

2 months ago

Startup Corsera Health aims to bring preventive heart medicine to the masses

FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment

BIIB

Investor's Business Daily

2 months ago

FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

BIIB

PR Newswire

2 months ago

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

BIIB

MT Newswires

2 months ago

Biogen's Postnatal Depression Drug Zuranolone Gets UK Approval

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

BIIB

Business Wire

2 months ago

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

BIIB

GlobeNewswire

2 months ago

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

BIIB

MT Newswires

2 months ago

Biogen, Eisai Launch Alzheimer's Disease Treatment in Austria; Germany to Follow

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

BIIB

GlobeNewswire

2 months ago

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

BIIB

Morningstar Research

2 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

BIIB

GlobeNewswire

2 months ago

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Biogen Stock: Analyst Estimates & Ratings

BIIB

Barchart

2 months ago

Biogen Stock: Analyst Estimates & Ratings

2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore

BIIB

StockStory

2 months ago

2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

BIIB

Business Wire

2 months ago

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials

BIIB

TipRanks

4 months ago

Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials

Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results

BIIB

Insider Monkey

4 months ago

Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results

BIIB

MT Newswires

4 months ago

Biogen Reports Mobility Gains with New Nusinersen Dose for Spinal Disorder

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

BIIB

GlobeNewswire

4 months ago

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

BIIB

MT Newswires

4 months ago

Biogen's Leqembi Has 'Meaningful Advantages' Over Lilly's Kisunla, Leading to Potential Billions in Sales, RBC Says

5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call

BIIB

StockStory

4 months ago

5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call

Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations

BIIB

Insider Monkey

4 months ago

Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations

Can Biogen Save Even More Kids With This New Drug?

BIIB

Investor's Business Daily

4 months ago

Can Biogen Save Even More Kids With This New Drug?

Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics

BIIB

GlobeNewswire

4 months ago

Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics

BIIB

MT Newswires

4 months ago

Biogen to Advance Investigational Spinal Muscular Atrophy Therapy to Registrational Studies

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

BIIB

Business Wire

4 months ago

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?

BIIB

Investor's Business Daily

4 months ago

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

BIIB

GlobeNewswire

4 months ago

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

BIIB

MT Newswires

4 months ago

RBC Raises Price Target on Biogen to $213 From $205, Keeps Outperform Rating

Biogen scores Cannes Festival win with dark humored campaign

BIIB

Pharma Voice

4 months ago

Biogen scores Cannes Festival win with dark humored campaign

Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia.

BIIB

Insider Monkey

4 months ago

Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia.

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

BIIB

Insider Monkey

4 months ago

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Biogen starts dosing in Phase III trial of Friedreich ataxia therapy

BIIB

Clinical Trials Arena

4 months ago

Biogen starts dosing in Phase III trial of Friedreich ataxia therapy

21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity

BIIB

Business Wire

4 months ago

21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity

H.C. Wainwright sees potential competition for Sage from Biogen

BIIB

TipRanks

4 months ago

H.C. Wainwright sees potential competition for Sage from Biogen

BIIB

MT Newswires

4 months ago

Biogen Launches Phase 3 Pediatric Trial of Omaveloxolone for Friedreich Ataxia Treatment

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

BIIB

GlobeNewswire

4 months ago

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

BIIB

Zacks

4 months ago

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer

BIIB

GlobeNewswire

4 months ago

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer

Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics

BIIB

Investor's Business Daily

4 months ago

Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics

Supernus makes depression drug play with $795m Sage buyout

BIIB

Pharmaceutical Technology

4 months ago

Supernus makes depression drug play with $795m Sage buyout

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million

BIIB

Investor's Business Daily

4 months ago

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million

Sage, following Setbacks, to sell to Supernus for $561M

BIIB

BioPharma Dive

4 months ago

Sage, following Setbacks, to sell to Supernus for $561M

Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025

BIIB

Insider Monkey

4 months ago

Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025

1 Profitable Stock with Exciting Potential and 2 to Avoid

BIIB

StockStory

4 months ago

1 Profitable Stock with Exciting Potential and 2 to Avoid

BIIB

MT Newswires

4 months ago

Biogen, UCB Say Dapirolizumab Pegol Phase 3 Study Shows Improvement in Fatigue, Reduction in Disease Activity

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

BIIB

GlobeNewswire

4 months ago

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?

BIIB

Zacks

5 months ago

Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

GlobeNewswire

5 months ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

StockStory

5 months ago

Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

Biogen and City Therapeutics to develop RNAi therapy

BIIB

Pharmaceutical Technology

5 months ago

Biogen and City Therapeutics to develop RNAi therapy

BIIB

Insider Monkey

5 months ago

Latest Biogen Inc. (BIIB) News on October 21, 2025

Share on Social Networks: